| Contributors |
|
v | |
| Chapter 1 An Introduction to Psychedelic Neuroscience |
|
1 | (24) |
|
|
|
|
|
|
|
2 | (1) |
|
2 Neurobiology of Psychedelic Therapy for Depression and Addiction |
|
|
3 | (2) |
|
3 Additional Therapeutic Mechanisms of Action |
|
|
5 | (1) |
|
4 Neurobiology of the Psychedelic Experience |
|
|
5 | (4) |
|
5 The Link Between Psychosis and the Psychedelic State |
|
|
9 | (3) |
|
|
|
12 | (2) |
|
|
|
14 | (2) |
|
|
|
16 | (7) |
|
|
|
23 | (2) |
| Chapter 2 The Renaissance in Psychedelic Research: What do Preclinical Models Have to Offer |
|
25 | (44) |
|
|
|
|
|
25 | (3) |
|
2 Renaissance in Psychedelic Research |
|
|
28 | (1) |
|
3 What Do Preclinical Models Have to Offer? |
|
|
29 | (2) |
|
|
|
31 | (7) |
|
|
|
34 | (2) |
|
4.2 Imaging/Electrophysiology |
|
|
36 | (2) |
|
|
|
38 | (3) |
|
|
|
41 | (3) |
|
7 First in Class Treatments for Addictive Disorders |
|
|
44 | (3) |
|
8 First in Class Treatments for Anxiety and Depression |
|
|
47 | (4) |
|
|
|
51 | (1) |
|
|
|
51 | (18) |
| Chapter 3 D-Lysergic Acid Diethylamide, Psilocybin, and Other Classic Hallucinogens: Mechanism of Action and Potential Therapeutic Applications in Mood Disorders |
|
69 | (28) |
|
|
|
|
|
|
|
|
|
|
|
|
|
70 | (1) |
|
2 Mechanism of Action of Psychedelics |
|
|
71 | (7) |
|
2.1 Serotonergic (5-HT) System |
|
|
71 | (2) |
|
|
|
73 | (2) |
|
|
|
75 | (2) |
|
|
|
77 | (1) |
|
3 The Renaissance of Psychedelic Medicine |
|
|
78 | (4) |
|
3.1 Clinical Research Into Depression and Anxiety |
|
|
78 | (3) |
|
3.2 Brain Imaging Studies |
|
|
81 | (1) |
|
4 Breaking the Norm With Unconventional Hallucinogens: Focus on Synthetic Tryptamine and Mescaline |
|
|
82 | (1) |
|
5 The Dark Side of Hallucinogens in Medicine: A Psychotic-like State |
|
|
83 | (3) |
|
6 Conclusions 86 Acknowledgments |
|
|
86 | (1) |
|
|
|
86 | (1) |
|
|
|
87 | (1) |
|
|
|
88 | (8) |
|
|
|
96 | (1) |
| Chapter 4 Common Neural Signatures of Psychedelics: Frequency-Specific Energy Changes and Repertoire Expansion Revealed Using Connectome-Harmonic Decomposition |
|
97 | (24) |
|
|
|
|
|
|
|
|
|
|
|
|
|
98 | (1) |
|
2 Connectome Harmonics as Brain States |
|
|
99 | (3) |
|
3 Neural Correlates of Psychedelics |
|
|
102 | (5) |
|
3.1 Time: Oscillatory Correlates of the Psychedelic State |
|
|
102 | (1) |
|
3.2 Space: Network Correlates of the Psychedelic State |
|
|
102 | (3) |
|
3.3 Neurophysiological Correlates of the Psychedelic State |
|
|
105 | (2) |
|
4 Connectome-Harmonic Correlates of Psychedelics |
|
|
107 | (8) |
|
4.1 Psychedelic Induced Energy and Power Changes in Brain Activity |
|
|
107 | (3) |
|
4.2 Frequency-Specific Energy Changes in Brain Activity in the Psychedelic State |
|
|
110 | (1) |
|
4.3 Psychedelic Induced Expansion of Connectome- Harmonic Repertoire |
|
|
110 | (1) |
|
4.4 Psychedelic Induced Changes in Whole-Brain Criticality |
|
|
111 | (4) |
|
|
|
115 | (1) |
|
|
|
116 | (5) |
| Chapter 5 A Case Report SPECT Study and Theoretical Rationale for the Sequential Administration of Ibogaine and 5-Me0-DMT in the Treatment of Alcohol use Disorder |
|
121 | (38) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
122 | (5) |
|
1.1 Ibogaine Background and Potential as a Treatment for Alcohol Use Disorder |
|
|
123 | (2) |
|
1.2 5-MeO-DMT Background and Potential as a Treatment for Alcohol Use Disorder |
|
|
125 | (2) |
|
1.3 Rationale for Sequential Treatment Protocol and Study |
|
|
127 | (1) |
|
|
|
127 | (2) |
|
|
|
129 | (3) |
|
|
|
129 | (2) |
|
|
|
131 | (1) |
|
|
|
132 | (4) |
|
|
|
132 | (4) |
|
4.2 Subjective Post-Treatment Report |
|
|
136 | (1) |
|
|
|
136 | (9) |
|
|
|
136 | (1) |
|
5.2 Case Findings and Theoretical Associations With Ibogaine in Treating Alcohol Use Disorders |
|
|
137 | (4) |
|
5.3 Case Findings and Theoretical Associations With 5-MeO-DMT in Treating Alcohol Use Disorders |
|
|
141 | (2) |
|
|
|
143 | (1) |
|
5.5 Potential Synergistic Effects of the Sequential Psychedelic Therapy Protocol |
|
|
143 | (2) |
|
|
|
145 | (1) |
|
|
|
146 | (1) |
|
|
|
146 | (13) |
| Chapter 6 Advances and Challenges in Neuroimaging Studies on the Effects of Serotonergic Hallucinogens: Contributions of the Resting Brain |
|
159 | (20) |
|
|
|
|
|
|
|
|
|
|
|
160 | (1) |
|
2 General Considerations of the Limitations of Neuroimaging Studies on Hallucinogens |
|
|
161 | (1) |
|
3 Alterations in Cerebral Blood Flow |
|
|
162 | (4) |
|
4 Alterations in Functional Connectivity |
|
|
166 | (5) |
|
4.1 Within and Between Network Functional Connectivity |
|
|
166 | (3) |
|
4.2 Global Functional Connectivity |
|
|
169 | (2) |
|
5 Summary and Conclusions |
|
|
171 | (2) |
|
|
|
173 | (6) |
| Chapter 7 Neurocognitive Effects of Cannabis: Lessons Learned from Human Experimental Studies |
|
179 | (38) |
|
|
|
|
|
|
|
179 | (3) |
|
1.1 Neurocognitive Effects of Cannabis: What Are We Missing? |
|
|
181 | (1) |
|
2 Cannabis Plant: Different Chemicals With Different Effects |
|
|
182 | (7) |
|
|
|
182 | (1) |
|
2.2 Disentangling the Effects of 9-THC, CBD, and Other Cannabinoids on Cognition |
|
|
183 | (5) |
|
2.3 A9-THC/CBD Ratio: Why It Is Important for the Effects of Cannabis on Cognition |
|
|
188 | (1) |
|
2.4 Need for Much More Research |
|
|
189 | (1) |
|
3 Development of Tolerance to Cannabis Effects: An Important Reason for Negative Findings in Experimental Studies |
|
|
189 | (11) |
|
|
|
189 | (1) |
|
3.2 Acute Cannabis Administration Impairs Cognitive Functioning Depending on the Extent of Previous Exposure |
|
|
190 | (3) |
|
3.3 Does Tolerance Develop Also for the Neuropsychiatric Effects of Cannabis? |
|
|
193 | (2) |
|
3.4 Neurophysiological and Neurochemical Correlates of Tolerance Development |
|
|
195 | (1) |
|
3.5 Pharmacokinetics and Pharmacodynamics of Tolerance Development |
|
|
195 | (4) |
|
3.6 Do Other Illicit Drugs Lead to Tolerance Through Similar Neurobiological Mechanisms? |
|
|
199 | (1) |
|
3.7 Development of Tolerance: Why It Is Important for Understanding the Effects of Cannabis on Cognition? |
|
|
200 | (1) |
|
4 What Does Cannabis Composition and Development of Tolerance Mean for the Potential Mechanisms Underlying the Effects of Cannabis on the Brain? |
|
|
200 | (1) |
|
5 Emerging Evidence for a Potential Role of Different Neurotransmitter Systems in the Manifestation of Cognitive and Neuropsychiatric Symptoms in the Context of Cannabis Use |
|
|
201 | (2) |
|
|
|
203 | (1) |
|
|
|
204 | (13) |
| Chapter 8 Ibogaine as a Treatment for Substance Misuse: Potential Benefits and Practical Dangers |
|
217 | |
|
|
|
|
|
218 | (8) |
|
|
|
218 | (1) |
|
|
|
218 | (1) |
|
|
|
218 | (1) |
|
1.4 Pharmacology, Pharmacokinetics and Pharmacodynamics |
|
|
219 | (1) |
|
|
|
220 | (1) |
|
1.6 Availability of Ibogaine |
|
|
220 | (2) |
|
|
|
222 | (1) |
|
1.8 Desired Effects and Uses |
|
|
222 | (4) |
|
|
|
226 | (6) |
|
|
|
226 | (1) |
|
|
|
226 | (2) |
|
|
|
228 | (1) |
|
|
|
229 | (1) |
|
2.5 Extent of Ibogaine Treatment |
|
|
230 | (1) |
|
2.6 Safety of Ibogaine Treatments |
|
|
231 | (1) |
|
|
|
232 | (9) |
|
|
|
232 | (1) |
|
|
|
232 | (3) |
|
3.3 Additional Non-UK Ibogaine-Related Fatalities |
|
|
235 | (3) |
|
3.4 UK Ibogaine-Related Deaths |
|
|
238 | (2) |
|
3.5 Summary Regarding Deaths |
|
|
240 | (1) |
|
|
|
241 | (1) |
|
|
|
241 | (1) |
|
|
|
242 | (1) |
|
4.3 Contra-Indications for Use |
|
|
242 | (1) |
|
|
|
242 | (1) |
|
|
|
242 | (1) |
|
5.2 A New Role for Herbal Products? |
|
|
243 | (1) |
|
|
|
243 | (1) |
|
|
|
243 | (1) |
|
|
|
244 | (1) |
|
|
|
244 | |
Lisainfo e-raamatute kohta